Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
IMUC's Cash-to-Debt is ranked higher than
88% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. IMUC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IMUC' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -32.41
Beneish M-Score: -19.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -738.67
IMUC's ROE % is ranked lower than
96% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. IMUC: -738.67 )
Ranked among companies with meaningful ROE % only.
IMUC' s ROE % Range Over the Past 10 Years
Min: -738.67  Med: -120.17 Max: -35.53
Current: -738.67
-738.67
-35.53
ROA % -160.59
IMUC's ROA % is ranked lower than
90% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. IMUC: -160.59 )
Ranked among companies with meaningful ROA % only.
IMUC' s ROA % Range Over the Past 10 Years
Min: -179.88  Med: -88.12 Max: -31.45
Current: -160.59
-179.88
-31.45
ROC (Joel Greenblatt) % -19650.96
IMUC's ROC (Joel Greenblatt) % is ranked lower than
84% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. IMUC: -19650.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMUC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79400  Med: -16598.23 Max: -11102.63
Current: -19650.96
-79400
-11102.63
3-Year EBITDA Growth Rate 2.20
IMUC's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. IMUC: 2.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IMUC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.1  Med: -6.3 Max: 103.3
Current: 2.2
-32.1
103.3
3-Year EPS without NRI Growth Rate 7.20
IMUC's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. IMUC: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMUC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.1  Med: -4.4 Max: 81.7
Current: 7.2
-28.1
81.7
GuruFocus has detected 2 Warning Signs with ImmunoCellular Therapeutics Ltd IMUC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMUC's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

IMUC Guru Trades in Q4 2016

Jim Simons 97,604 sh (New)
» More
Q1 2017

IMUC Guru Trades in Q1 2017

Jim Simons 116,804 sh (+19.67%)
» More
Q2 2017

IMUC Guru Trades in Q2 2017

Jim Simons 131,604 sh (+12.67%)
» More
Q3 2017

IMUC Guru Trades in Q3 2017

Jim Simons 680,404 sh (+417.01%)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:TSXV:HEM, OTCPK:AMAR, OTCPK:CGYG, OSTO:ANNX, OTCPK:TSOI, OSTO:CMOTEC B, OTCPK:RGBP, XSAT:NORI, TSXV:MFS, OTCPK:MTST, TSXV:JEN.H, XCNQ:LILY, OTCPK:SGBI, WAR:RDG, XSAT:QUIA, OTCPK:ATMS, OTCPK:ISCO, STU:BMP, BOM:506128, TSXV:KNE » details
Traded in other countries:KOL1.Germany,
Headquarter Location:USA
ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

Ratios

vs
industry
vs
history
EV-to-EBIT -0.07
IMUC's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. IMUC: -0.07 )
Ranked among companies with meaningful EV-to-EBIT only.
IMUC' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -4.5 Max: 2.3
Current: -0.07
-19.9
2.3
EV-to-EBITDA -0.07
IMUC's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. IMUC: -0.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMUC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.9  Med: -4.5 Max: 2.3
Current: -0.07
-19.9
2.3
Current Ratio 0.92
IMUC's Current Ratio is ranked lower than
93% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IMUC: 0.92 )
Ranked among companies with meaningful Current Ratio only.
IMUC' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 14.71 Max: 76.13
Current: 0.92
0.57
76.13
Quick Ratio 0.92
IMUC's Quick Ratio is ranked lower than
91% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. IMUC: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
IMUC' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 14.71 Max: 76.13
Current: 0.92
0.57
76.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.70
IMUC's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. IMUC: -33.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMUC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -30.2 Max: -19.3
Current: -33.7
-51.6
-19.3

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -1428.57
IMUC's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. IMUC: -1428.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMUC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5421.4  Med: -11.6 Max: 3471
Current: -1428.57
-5421.4
3471

More Statistics

EPS (TTM) $ -4.76
Beta0.35
Short Percentage of Float48.73%
52-Week Range $0.25 - 4.27
Shares Outstanding (Mil)23.79

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $)
EPS ($) -3.83 -0.64 -0.57 -0.76
EPS without NRI ($) -3.83 -0.64 -0.57 -0.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}